Posted by Michael Wonder on 19 Jul 2017
NICE approves more tolerable treatment for blood cancer
19 July 2017 - Around 2,200 patients a year with multiple myeloma are set to benefit from a new, tolerable treatment on the NHS following approval by NICE.
Carflizomib does not cause serious side effects, such as chronic pain from damaged tissue, to the same extent as current treatments, the independent committee at NICE found.
The drug, also called Kyprolis and manufactured by Amgen, treats patients with multiple myeloma whose cancer has come back after one round of treatment. Previous treatment must not include a drug called bortezomib.
